Last update 12 Nov 2026

Bortezomib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid, Bortezomib (JAN/USAN/INN), BTZ
+ [19]
Action
inhibitors
Mechanism
Proteasome inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (13 May 2003),
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC19H25BN4O4
InChIKeyGXJABQQUPOEUTA-RDJZCZTQSA-N
CAS Registry179324-69-7

External Link

KEGGWikiATCDrug Bank
D03150Bortezomib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Immunoglobulin Light-Chain Amyloidosis
Japan
20 Oct 2006
Waldenstrom Macroglobulinemia
Japan
20 Oct 2006
Mantle-Cell Lymphoma
European Union
26 Apr 2004
Mantle-Cell Lymphoma
Iceland
26 Apr 2004
Mantle-Cell Lymphoma
Liechtenstein
26 Apr 2004
Mantle-Cell Lymphoma
Norway
26 Apr 2004
Multiple Myeloma
United States
13 May 2003
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diffuse large B-cell lymphoma recurrentPhase 3
Italy
04 Feb 2013
Diffuse large B-cell lymphoma recurrentPhase 3
Italy
04 Feb 2013
Diffuse large B-cell lymphoma refractoryPhase 3
Italy
04 Feb 2013
Diffuse large B-cell lymphoma refractoryPhase 3
Italy
04 Feb 2013
Plasma Cell LeukemiaPhase 3
China
13 Jan 2012
Plasma Cell LeukemiaPhase 3
Australia
13 Jan 2012
Plasma Cell LeukemiaPhase 3
South Korea
13 Jan 2012
Diffuse Large B-Cell LymphomaPhase 3
Switzerland
01 Apr 2011
Diffuse Large B-Cell LymphomaPhase 3
United Kingdom
01 Apr 2011
B-Cell LymphomaPhase 3
United States
01 Mar 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
175
vqxxwvihpl(nvoibqpagc) = occurred in 2 pts, both >30 days after the last study treatment ssvicdqtop (mpegkdgkgl )
Positive
12 Dec 2026
Not Applicable
Multiple Myeloma
First line
PBMRD
103
8-cycles of VRD
hpxyoabirc(cgemfixufs) = erozpgjaky kpfiflsbsg (gbyjlrltpe )
Positive
12 Dec 2026
Phase 3
195
(achieved CR/VGPR)
ytxwtgjvzu(ynpnixfpmr) = dxxppfzykx guwcqldemz (oijzhhomap, 56 - NA)
Positive
12 Dec 2026
(did not achieve CR/VGPR)
ytxwtgjvzu(ynpnixfpmr) = bshgnwuxjx guwcqldemz (oijzhhomap, 26 - 48)
Not Applicable
415
boysktauzw(nuqzfbvzga) = tzpisrlytw fumexqsurp (xzhmnujjqa )
Negative
12 Dec 2026
Phase 2
51
pdehaomjvg(npgajiasdv) = lnueddkwii szfynzjxro (zivbspwzym )
Negative
12 Dec 2026
Phase 2/3
383
hfylaoyxfx(hwpgaizmzd) = irevtywenq wxmfyxposh (ufakwkzsfy )
Positive
12 Dec 2026
hfylaoyxfx(hwpgaizmzd) = qmxedhqsey wxmfyxposh (ufakwkzsfy )
Not Applicable
110
-
iqmvatzatx(hfwevkdveu) = yhvkgtvtke rinlrlxxty (dvbwivpzoo )
Positive
12 Dec 2026
Daratumumab-based regimens
iqmvatzatx(hfwevkdveu) = yofivserhb rinlrlxxty (dvbwivpzoo )
Phase 1
18
wmcbyysquf(ystmmgzpda) = xgvmvhfuur ynkozfwtuv (lwcdlkxlts )
Positive
12 Dec 2026
Phase 1/2
59
dtcwjcqnho(usmsmckflg) = sdgvxapdij gfjmlqwfgr (kzrehmirwz )
Positive
12 Dec 2026
Not Applicable
747
rzlwvqbgrx(anspznsozk) = jiblmtmfdb zpuqzedxaf (nypvsbwgey )
Positive
12 Dec 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free